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Summary. Optimal biomarker combinations for treatment-selection can be derived by
minimizing total burden to the population caused by the targeted disease and its treat-
ment. However, when multiple biomarkers are present, including all in the model can
be expensive and hurt model performance. To remedy this, we consider feature se-
lection in optimization by minimizing an extended total burden that additionally incorpo-
rates biomarker measurement costs. Formulating it as a 0-norm penalized weighted-
classification, we develop various procedures for estimating linear and nonlinear combi-
nations. Through simulations and a real data example, we demonstrate the importance
of incorporating feature-selection and marker cost when deriving treatment-selection
rules.
Keywords: Biomarker cost; Feature selection; L0 penalization; Treatment selec-
tion; Weighted support vector machines.
1. Introduction.
A considerable amount of recent biometric research is being conducted in the ‘person-
alized medicine’ framework, because it has been well accepted now that heterogeneity
can exist among individual subjects’ response to treatment in many disease settings.
The characteristics contributing to this heterogeneity may include patient demograph-
ics, genetic/genomic information or other biological markers, henceforth referred to
as treatment-selection biomarkers. These biomarkers can be effectively used to select
optimal therapies for individuals in order to optimize this clinical outcome. Also it
is important to remember that a single biomarker may not sufficiently explain this
heterogeneity, and multiple biomarkers may need to be combined to build the correct
statistical framework to optimize the process of treatment selection.
The direct approach to identifying these optimal marker combinations in treatment
selection involves parametric modeling of the disease risk conditional on biomarkers,
treatment assignment and other baseline patient characteristics, and recommending
treatment assignments based on whether the predicted risk under treatment is lower
than the predicted risk under no treatment. This framework was first introduced
by Song and Pepe (2004), and studied extensively in Foster et al. (2011); Qian and
Murphy (2011); Lu et al. (2013). Treatment selection rules based on parametric risk
models rely heavily on the correct specification of this model, which is often challeng-
ing given the complexity of biological mechanisms. An alternate, much more robust
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approach is to build optimization algorithms to minimize (or maximize) a desired
criterion. This criterion, often called the objective function, is formulated based on
relevant goals for treatment selection, and the optimization algorithm tries to find
the best marker combination that optimizes it. These methods (also called indirect
approaches) can be made completely nonparametric and assumption free and much
more robust to model misspecifications. Zhang et al. (2012a,b) proposed finding the
optimal marker combination within a pre-specified class by optimizing an estimator
of the overall population mean outcome. Zhao et al. (2012) approached the same as
an outcome-weighted learning problem and derived optimal treatment-selection rules
using a weighted support vector machine method.
In Huang and Fong (2014), the authors proposed a new method to identify linear
and nonlinear marker combinations by directly optimizing a targeted criterion func-
tion in the manner of Zhang et al. (2012a) and Zhao et al. (2012). However, the
targeted criterion differed from others as adverse side-effects and/or cost incurred by
the treatment were considered along with the event rates of the targeted disease in
establishing the objective function. This was a crucial extension, as reducing safety
events or cost of administering the treatment is often a valid policy goal (see Vickers
et al., 2007). The authors formulated the optimization problem as minimization of a
weighted sum of 0-1 loss, and used the ramp loss as an approximation of the 0-1 loss.
In this article, we extend the idea of Huang and Fong (2014) in creating an augmented
target criterion that takes on the additional challenge of controlling for the number of
markers in the risk model as well. This is crucial for two vital reasons: (a) Measuring
biomarkers can be expensive with respect to both time and money, and possibly inva-
sive too. It is therefore of significant interest to limit the number of biomarkers that
need to be collected for an individual to selecting his/her optimal treatment. (b) As
discussed earlier, our original problem requires us to find optimal biomarker combi-
nations to explain the disease response heterogeneity in individuals, but finding this
optimal combination can be difficult in the presence of redundant markers that do not
contribute to treatment selection. This may lead to overfitting and result in overly
complex selection rules that have poor prediction performance. One way to deal with
this ‘curse of dimensionality’ is through marker selection. Recently a lot of attention
has been directed to effect modifier selection in precision medicine. For example, in
Zhao (2017), the authors studied selective inference in effect modification models via
LASSO; in Liang (2017), the authors constructed sparse decision rules in the context
of concordance-assisted learning; and in Shi (2018), the authors proposed a penalized
multi-stage A-learning algorithm for deriving the optimal dynamic treatment regime.
Although these feature selection methods are all relevant to the broad genre of preci-
sion medicine, each of them target a very specific problem, which are quite different
from our objective of penalized optimization of the single stage targeted objective
function, where still only limited research exists: some insight into marker selection in
treatment recommendation problems were briefly studied by Huang (2016) and Zhou
et al. (2015), where both targeted minimization of disease rate in treatment selection.
To address these issues along with the original goals of treatment selection, we
reformulate the criterion for treatment selection by associating a cost for measuring
each biomarker in creating the optimal rule. The optimization problem can be written
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as minimization of a weighted sum of 0-1 loss, but with a L0 penalty added for the
number of markers in the model. In this article, we adopt the usual hinge loss convex
relaxation of the 0-1 loss and perform a comprehensive investigation and comparison
of various algorithms for solving this optimization problem. In linear support vector
machines, L0 feature extraction is a well-researched problem (see Bradley and Man-
gasarian, 1998; Weston et al., 2003; Mangasarian, 2006; Huang et al., 2010), although
it is a much more challenging problem in nonlinear support vector machines (see Man-
gasarian and Wild, 2007). However, it is worth noting that our setting differs from
a simple classification format in two vital aspects: (a) although the treatment selec-
tion objective can be rewritten into a (weighted) classification problem (as shown in
Section 2), it is still in essence a fundamentally different problem from classification,
and feature selection techniques in SVMs have not been studied under this context,
and (b) weighted SVM is a more complicated optimization problem than the standard
SVM, where the constraint on each support vector varies according to the weight as-
sociated with it, and research into feature extraction under this setting has also been
fairly limited till now. Some work has been done to extend the SCAD penalty with
the weighted linear support vector machines with special forms of such weights (see
Jung, 2013), but beyond that, there hasn’t been any targeted investigation of such as
per our knowledge. These two reasons make these explorations vitally important.
Thus, the biggest contribution of this article is to combine the methodological ad-
vances in two different areas of research, advances in indirect approaches to treatment
selection through kernelized methods and those in feature selection techniques in non-
parametric statistical learning methods like SVMs. We believe that combining these
two areas of research is a novel methodological formulation in itself. Additionally each
of these feature selection methods has been translated from the standard SVM frame-
work to the weighted SVM formulation to match the proposed objective. Moreover,
adding a penalty for the number of markers in the model redefines the objective func-
tion as well, which has been used in conjunction with these feature selection techniques
- for example, in choosing tuning parameters for a given feature selection method, we
propose the use of a generalized cross validation (GCV) technique that utilizes the
whole objective criterion including the penalty for the number of markers.
The article continues in the following manner: In Section 2, we establish the
problem of minimizing the total disease, treatment, and marker measurement cost
in treatment-selection, and discuss marker selection in conjunction with treatment se-
lection. We briefly discuss various methods built for support vector machines, adapted
specifically for the weighted classification setup, for deriving the best linear and non-
linear marker combinations in order to optimize the desired objective function. In
Section 3, we set up different simulation examples to test the strength of these linear
and nonlinear feature selection methods, modified for our setting, and discuss the re-
sults. Then in Section 4, we illustrate the application of our methods using a real data
example from an HIV vaccine trial. And finally, in Section 5, we discuss our findings
regarding the use of these feature selection methods and the impact of incorporating
marker measurement cost into treatment selection, and link to additional materials
are presented in the Supplementary Section 6.
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2. Methods.
In this article, we consider the problem of finding optimal treatment selection rules
for a binary clinical outcome Y (0 for nondiseased and 1 for diseased) based on a set
of p ≥ 1 candidate markers collected from an individual’s biological characteristics
(the solution we propose is applicable to clinical outcome measured in continous scale
as well). Denote this set of candidate markers by Xp = {X1, . . . , Xp}. For a given
subset of markers X ⊆ Xp, we consider marker based treatment selection rules of
the form A(X) = I(f(X) > 0), where f ∈ FX and FX denotes a class of functions
spanning over X, and I(·) is the indicator function. The above then translates to the
rule: A = 0 for not treating, and A = 1 for treating. The treatment-selection benefit
of a decision rule A(X) can be quantified by EA(X)(Y ), the expected disease rate
in the population as a result of treatment selection based on A(X) (Song and Pepe,
2004; Qian and Murphy, 2011). This measure has been widely accepted as a crucial
metric in recent literature (Zhao et al., 2012; Zhang et al., 2012a). Although EA(X)(Y )
characterizes the burden of disease upon the population, one may be concerned with
additional burden associated with a treatment regimen, such as its side effects and/or
the monetary cost of its implementation. Hence it might be preferable to search
for treatment-selection strategies that take these aspects into consideration as well.
Huang and Fong (2014) proposed to incorporate additional burden associated with a
treatment regimen, such as due to its side effects of monetary cost, by pre-specifying a
treatment/disease harm ratio such that each burden type can be put on the same scale.
Following the decision-theoretic framework of Vickers et al. (2007), let δ1 be a pre-
specified ratio of the burden per treatment relative to the burden per disease event, and
let Y (1) and Y (0) indicate the potential disease outcome if a subject were to receive
or not receive the treatment. Then the total burden due to disease and treatment for
A(X), represented in the unit of burden per disease event (see Huang and Fong, 2014)
is given as EA(X)(Y )+E{δ1×A(X)} =
∑1
a=0E [Y (a)× I{A(X = a)}]+δ1×E{A(X)}.
And the best treatment-selection rule is derived as the one that minimizes this total
burden.
In this article we further take into consideration the cost of measuring biomarkers in
deriving the optimal treatment-selection rule, under the expectation that inclusion of
the burden of measuring biomarkers in the criterion function can lead to the derivation
of more cost-effective treatment-selection rules in the sense of achieving desired public
health impact under the guidance of a parsimonious biomarker panel. We make the
following assumptions: (i) measurement of each biomarker induces roughly equal cost,
and (ii) the cost of measuring one biomarker is δ2 times the burden per disease event.
Then the total burden due to disease, treatment, and biomarker measurement for a
treatment-selection rule A(X) can be represented in the unit of the burden per disease
event as
θ = EA(X)(Y ) + E{δ1 ×A(X)}+ δ2 × dim(X)
=
1∑
a=0
E [Y (a)× I{A(X) = a}] + δ1 × E{A(X)}+ δ2 × dim(X). (1)
Note: Although we assume a roughly equal cost for each biomarker for simplicity in
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this paper, it is straightforward to extend it to a setting where each biomarker has a
different cost. Biomarkers which are absolutely essential to collect can be considered
to have no cost at all, or there may be several groups of biomarkers, such that each
group has a different cost depending on its burden and importance for the population
of interest. In such situations, the penalty δ2×dim(X) can be replaced by
∑dim(X)
i=1 δ2,i
where δ2,i ≥ 0 is the cost associated with the biomarker Xi, and our methods can still
be applied as described with only minor modifications.
We propose to derive an optimal treatment-selection rule by minimizing this quan-
tity θ. Suppose there exists an ‘optimal’ or ‘correct’ set of p0 biomarkers X0 within the
list of biomarkers measured, such that X0 = {X∗1 , . . . , X∗p0} ∈ Xp, which when com-
bined through an oracle rule f0 minimizes θ. Thus, we can write the above problem
as,
f0 = arg min
X⊆Xp
min
f∈FX
θ (2)
Note that under this setup, f0 ∈ FX0 . In practice, it is important to have a sensible
way to specify the values or the range of values for δ1 and δ2. Choice of these cost
ratios can be facilitated based on information of the monetary cost for controlling
the targeted disease, for applying the treatment, and for biomarker measurement, as
in our data example of making recommendation for HIV vaccine, presented later in
Section 4.
Now imagine data from a two-arm randomized trial with the treatment indicator T
taking values 0 and 1, to refer being untreated and treated, respectively. Let n0 and n1
indicate the number of subjects in the untreated and treated arms, respectively. Thus
we have i.i.d. samples of the form {Yi,Xi, Ti} for i = 1, . . . , n with n = n0 +n1. As in
Huang and Fong (2014), we assume: (i) stable unit treatment value (SUTVA) (Rubin,
1980) and consistency: Y (0), Y (1) of one subject is independent of the treatment
assignments of other subjects, and given the treatment a subject actually received,
a subject’s potential outcomes equal the observed outcomes; (ii) ignorable treatment
assignments assumption: T ⊥ Y (0), Y (1)|X. Assumption (i) is plausible in trials
where participants do not interact with one another and assumption (ii) is ensured by
randomization. Under the above assumptions, it can be shown that,
θ = E [Y × {1−A(X)}|T = 0] + E [Y ×A(X)|T = 1] + δ1 × P{A(X) = 1}+ δ2 × dim(X)
= E(Y |T = 0)− E [A(X)× {Risk0(X)−Risk1(X)− δ1}] + δ2 × dim(X) (3)
where Risk0(X) = P (Y = 1|X, T = 0) and Risk1(X) = P (Y = 1|X, T = 1) are the
risk of Y conditional on X among the untreated and treated, respectively.
Huang and Fong (2014) showed that when δ2 = 0, an optimal rule A(X) can be ob-
tained as A(X) = 1 if Risk0(X)−Risk1(X) > δ1, and A(X) = 0 otherwise. But when
δ2 is positive, such a strategy alone wouldn’t exactly work as we need to also control the
number of markers in the model. Since the quantity δ2 imposes an L0 penalty on the
set of markers X, one ad hoc method may be to use standard regression-based methods
with L0/L1 penalization to estimate the quantities Risk0(X) and Risk1(X) and then
derive the optimal treatment-selection rule as A(X) = I{Risk1(X)−Risk0(X) > δ1}.
But note that the above procedure may lead to suboptimal rules with respect to our
goal of minimizing θ.
Alternatively, following the strategy in Zhang et al. (2012a), Zhao et al. (2012) and
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Huang and Fong (2014), we can consider a class of rules for treatment recommendation
based on functionals of the form f(X) (belonging to some functional class FX on X),
and a given threshold (usually 0). In particular, we let A(X) = I{f(X) > 0} with I(·)
the indicator function, f(X) = b + g(X) with g(X) a function of markers X. Then,
assuming randomization does not depend on X for simplicity, θ can be expressed as
E[Y×T×I{f(X)>0}]
P (T=1) +
E[Y×(1−T )×I{f(X)≤0}]
P (T=0) + δ1 × P{f(X) > 0} + δ2 × dim(X). The
optimal f(X) can be found by minimizing the empirical estimate of θ, that is,
fˆ = arg min
X⊆Xp
min
f∈FX
{
n∑
i=1
{Yi × Ti
n1
− Yi × (1− Ti)
n0
+
δ1
n
} × I{f(Xi) ≤ 0}+ δ2 × dim(X)
}
.
Therefore, we can formulate this problem as the minimization of the sum of a
weighted sum of 0-1 loss and a term proportional to the number of biomarkers. That
is, fˆ can be found as the minimizer of
n∑
i=1
WiI {f(Xi) ≤ 0} /n+ δ2 × dim(X), (4)
with the case-specific weight Wi = W1i = −
{
Yi×Ti
n1/n
− Yi×(1−Ti)n0/n + δ1
}
. Other
types of weights such as control-specific or case-control mixture weights or
their robust substitutes can also be adopted and are discussed in Huang and
Fong (2014). For example, the robust substitute for the case-only weights
W rob1i = −
{
Yi×Ti
n1/n
− Yi×(1−Ti)n0/n + pi−Tipi R̂isk0 + pi−Ti1−pi R̂isk1 + δ1
}
, where R̂isk0(X) and
R̂isk1(X) are risk estimates obtained from a working model and pi = P (T = 1). It is
worthwhile to note that since the minimization of (3) is equivalent to the minimiza-
tion of E[I{f(X) ≤ 0} × {Risk0(X) − Risk1(X) − δ1}], any consistent estimate of
Risk0(X)−Risk1(X)− δ1 can also serve as weights in (4).
Note that if we are only interested in combining a set of candidate biomarkers
without performing any variable selection, then it is not necessary to include the
biomarker measurement cost in the criterion function as in Huang and Fong (2014).
However, in the presence of a large number of biomarkers, incorporation of marker
cost will impact the features selected in the estimated rule.
2.1. Treatment selection as a weighted Support Vector Machines problem.
In this section, we consider the minimization of the regularized loss function (4),
conditional on a pre-specified set of weights W . Since
∑n
i=1WiI {f(Xi) ≤ 0} /n ∝∑n
i=1 |Wi|I {sgn(f(Xi)) 6= sgn(Wi)} /n, (4) can be reformulated as
n∑
i=1
|Wi|I {sgn(f(Xi)) 6= sgn(Wi)} /n+ δ2 × dim(X) (5)
Note that (5) is a weighted classification problem where Y ∗i = sgn(Wi) = {−1, 1}
is the true binary classes, sgn{f(Xi)} is the predicted binary class based on X, and
|Wi| is the subject specific weight. This type of problem can be resolved using the
weighted support vector machine (Lin and Wang, 2002), based on Xi, Yi, and |Wi|.
Since minimization of a weighted sum of 0-1 loss is non-convex and intractable, we
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look to replace the 0-1 loss with a convex surrogates; the hinge loss is often used in this
context. The hinge loss, given as h(u) = max(0, 1− u) has been proven to be a useful
surrogate to the classification loss, such that the term |Wi|I {sgn(f(Xi)) 6= sgn(Wi)}
in (5) is replaced by |Wi|h (f(Xi)× sgn(Wi)). It is worth noting that the hinge loss
penalizes departure of a decision rule from its observed class label, based on the
extent of this departure, which the classification loss fails to do. The hinge-loss SVM
formulation of the above problem is given as,
min
X⊆Xp
min
f∈FX
n∑
i=1
|Wi|max(1− sgn(Wi)× f(Xi), 0)/n+ δ2 × dim(X) (6)
This is the L0 penalized weighted support vector machines framework. In SVMs, the
functional space FX is generally restricted to be a reproducing kernel Hilbert space
HX(kx), represented uniquely by its kernel kx. Before considering the solution to (6),
we first review the weighted support vector machines formulation from Lin and Wang
(2002), where the square of the Hilbert space norm ‖ · ‖HX is used instead of the L0
norm. For a given subspace X ∈ Xp, we define it as:
min
f∈HX
n∑
i=1
|Wi|max(1− sgn(Wi)× f(Xi), 0)/n+ λ‖f‖2HX (7)
In linear support vector machines, F linX = {fβ,b0 : fβ,b0(x) = 〈β,x〉 + b0, x ∈ X, β ∈
Rdim(X), b ∈ R} is used for optimization, an RKHS with the Euclidean inner prod-
uct as its kernel function, kx(x1,x2) = 〈x1,x2〉. The Hilbert norm ‖f‖2HX in this
case becomes the usual Euclidean L2 norm on the linear combination weights ‖β‖2,
and the estimated decision functions fˆ can be expressed as a linear combination of
the input marker set X. However, as many optimal marker combination for treat-
ment selection may not be among linear combinations of the input markers, it is
important to extend FX to include more complex nonlinear functions. This can be
achieved by considering transformations of the feature space through feature maps
of the form φ(x), the appropriate RKHS for which is the one with the kernel kx
satisfying kx(x1,x2) = 〈φ(x1), φ(x2)〉. Examples of popular nonlinear kernels in-
clude the polynomial kernel of dth degree kx(xi,xj) = (1 + 〈xi,xj〉)d and the ra-
dial basis function (RBF) kernel kx(xi,xj) = exp
(−γ‖xi − xj‖2) with γ as a tuning
parameter. The resulting SVM solution at a given covariate vector x0 is given as
f(x0) =
∑n
j=1 αjk(x0,xj)+β0, where αi ∈ R’s are the trained weights on the support
vectors k(·,xj) and b0 ∈ R is the estimated global constant.
2.2. Weighted versus unweighted support vector machines.
The weighted support vector machines is a well-known technique for classification.
First proposed by Lin and Wang (2002), who called it the “fuzzy support vector
machines” or FSVM, it has been further applied and studied in subsequent works (Fan
and Ramamohanarao, 2005; Yang et al., 2007; Zhao et al., 2012, see for example).
In essence, the weighted support vector machines becomes a very important tool
in classification, when some training points are more important than others for the
given problem. The main difference in solving the weighted SVM and the standard
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unweighted SVM lie in the constraints that we put on the support vectors in the
dual formulation of the problem. To see this, let us write down the dual of the
unweighted SVM below and note the changes that can transform it into a weighted
SVM problem. Let us denote Y ∗i = sgn(Wi) and qi = |Wi|, and then see that the
unweighted squared Hilbert loss penalized SVM is given as minf∈HX
∑n
i=1 max(1 −
Y ∗i f(Xi), 0)/n+ λ‖f‖2HX , the dual of which is given as,
max
α
n∑
i=1
αi − 1
2
n∑
i=1
n∑
j=1
αiαjY
∗
i Y
∗
j kX(xi,xj) subject to
n∑
i=1
Y ∗i αi = 0, 0 ≤ αi ≤ C,
(8)
for C = 1/(2λn). The dual of (7) differs from (8) only through the constraints that
we put on the αis. In the unweighted SVM, the upper-bound for each of αi is the
fixed constant C, while in the weighted SVM, the upper bound for each αi is further
multiplied by the quantity qi and thus becomes C × qi (that is, 0 ≤ αi ≤ Cqi).
Intuitively it just means that αi, the coefficient associated with a given sample, is
each constrained differently according to their weight.
2.3. Identifying optimal biomarker combinations in the linear space.
As noted before, variable selection is a key motivation in our pursuit to solve (6), which
isn’t an inherent feature of the support vector machines framework of (7). The Hilbert
norm provides some control on the overcomplexification of the estimated functions,
but without performing any variable selection. Many authors have proposed to use the
L1 and L0 penalty either as a replacement or in conjunction with the L2 norm in the
linear SVMs. First of all, note that solving (6) is combinatorially a very hard problem
(see Amaldi and Kann, 1998), but the zero norm is directly related to finding minimal
subsets and can provide optimal feature extraction if properly implemented. There are
however many feature extraction algorithms for the unweighted linear support vector
machines that do not rely on the L0 norm for selection (see for example Mangasarian,
2006; Zhang et al., 2006). To this effect, in this article, we also look at alternate ways
to perform feature selection in support vector machines, instead of focusing solely
on solving (6). Here, we build our optimization approaches on some of the most
commonly used algorithms for unweighted SVMs. That is, we modify each of them to
cater to the weighted version of the algorithm, and we will see how it paves the way
for directly or indirectly solving (6) in the linear space. We now briefly introduce each
method below, along with their modified objective function under the weighted SVM
setup, while a more detailed description of each is reserved for the Supplementary
Section (see Web Appendix ??).
(a) L1 weighted support vector machines (L1 WSVM), that utilizes the L1 norm for
penalization instead of the squared Hilbert norm, built upon Mangasarian (2006),
with objective function,
min
β,β0
n∑
i=1
qi max{1− Y ∗i (〈Xi,β〉+ β0), 0}/n+ λ
p∑
j=1
|βj |. (9)
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(b) SCAD applies the smoothly clipped absolute deviation penalty (Zhang et al., 2006)
to the WSVM objective function ,
min
β,β0
n∑
i=1
qi max{1− Y ∗i (〈Xi,β〉+ β0), 0}/n+
p∑
j=1
pλ(|βj |), (10)
pλ(|β|) = λ|β|1(|β| ≤ λ)− |β|
2−2aλ|β|+λ2
2(a−1) 1(λ < |β| ≤ aλ) + (a+1)λ
2
2 1(|β| > aλ).
(c) elastic SCAD, that uses a mixture of the SCAD penalty and the L2 norm,
min
β,β0
n∑
i=1
qi max{1− Y ∗i (〈Xi,β〉+ β0), 0}/n+
p∑
j=1
pλ1(|βj |) + λ2‖β‖2. (11)
(d) feature selection concave (FSV), built on a concave minimization algorithm origi-
nally proposed by Bradley and Mangasarian (1998), achieves approximate L0 pe-
nalization in weighted SVMs through solving,
min
β,β0,v
∑
Y ∗i =1
qi max{1− 〈Xi,β〉 − β0, 0}∑n
i=1 I(Y
∗
i = 1)
+
∑
Y ∗i =−1 qi max{1− 〈Xi,β〉 − β0, 0}∑n
i=1 I(Y
∗
i = −1)
+
∑
j
αe−αv
∗
j (vj−v∗j ) subject to − v ≤ β ≤ v, (12)
(e) approximation of the zero norm minimization (AROM), that achieves approximate
L0 penalization (see Weston et al., 2003) by solving the following objective function
iteratively. It initializes a vector z = (1, . . . , 1), and at each successive step, it resets
z as z × β,
min
β,β0
n∑
i=1
qi max{1− Y ∗i (〈zi ∗Xi,β〉+ β0), 0}/n+ λ
p∑
j=1
|βj |2 (13)
where x ∗w = (x1w1, . . . , xpwp).
(f) L0 weighted support vector machines (L0 WSVM), built on the works of Huang et
al. (2010), that achieves L0 norm in weighted support vector machines through an
iterative scheme, by solving the following objective function at the tth step,
(β(t), β
(t)
0 ) = arg min
β,β0
n∑
i=1
qiξi/n+ λβ
TΛ(t−1)β, (14)
subject to Y ∗i (〈Xiβ〉 + β0) ≥ 1 − ξi, ξi ≥ 0, i = 1, . . . , n, where Λ(t−1) =
diag(1/|β(t−1)1 |2, . . . , 1/|β(t−1)p |2).
2.4. Identifying optimal biomarker combinations in the nonlinear space.
In this section, we consider the derivation of best biomarker combinations in the
nonlinear space, as most optimal marker combinations for treatment-selection rules
may not be among the linear combinations of the input markers. Feature selection
is a fairly straightforward procedure for linear SVM classifiers, but it is a much more
challenging problem in nonlinear support vector machines (see Mangasarian and Wild,
2007). For example, in the linear support vector machines, we can use the L1 or L0
norm instead of the Hilbert norm. However, when similar techniques are applied to
nonlinear SVM classifiers, we have reduction in the number of support vectors but not
9
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Fig. 1. Schematics of riskRFE in nonparametric estimation
in the number of input space features (Fung and Mangasarian, 2004). So although
the dimensionality of the transformed space is reduced, it does not provide any direct
reduction of input space features. A few procedures have recently been developed
however to deal with feature selection in the original input space under nonlinear
feature maps (see Dasgupta et al., 2013; Allen, 2013), but not a lot of them have been
developed with the goal of L0 penalization. We will investigate some of these newly
developed methods here, but under the more generalized setting of weighted support
vector machines. We briefly introduce each method below, along with their modified
objective function under the weighted SVM setup, while a more detailed description
of each is reserved for the Supplementary Section (see Web Appendix ??).
(a) risk recursive feature elimination (riskRFE), a newly developed, powerful wrapper
technique based on recursive computation of the learning function (see Dasgupta
et al., 2013), that works both in the linear and the nonlinear space (see Figure 1
for a flow chart of the algorithm).
(b) kernel iterative feature extraction (KNIFE), that achieves feature selection in
nonlinear SVMs, by optimizing a feature-regularized loss function (by weight-
ing features within the kernel), iteratively (see Allen, 2013). For kw (x1,x2) =
k (w ∗ x1,w ∗ x2), the weighted version of the algorithm solves,
min
β0,α,w
n∑
i=1
qi max{1− Y ∗i (
n∑
j=1
αjkw(xi,xj) + β0), 0}/n+ λ1αTkwα+ λ2‖w‖1
subject to 0 ≤ wj < 1 for all j = 1, . . . , p. (15)
(c) kernel penalized weighted support vector machines (KP-WSVM), built on the works
of Maldonado et al. (2011) for feature selection in nonlinear SVMs, that relies on
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penalizing each feature’s use in the dual formulation.
min
β0,α,w
n∑
i=1
qi max{1− Y ∗i (
n∑
j=1
αjkw(xi,xj) + β0), 0}/n+ λ
n∑
j=1
(1− e−βwj )
subject to wj ≥ 0 ∀j = {1, . . . , n}. (16)
The approximated L0 penalty in the above objective function can also be replaced
by a L1 norm.
3. A simulation study
In this section, we investigate the performance of the aforementioned feature selection
methods in conjunction with the weighted support vector machines algorithms in
minimizing the L0 penalized sum of the weighted classification loss as in (5) in various
simulation settings that we describe below.
3.1. The simulation setup
We consider data from 1:1 randomized trial of size n = 500 for studying the perfor-
mance of our proposed strategy. The linear feature selection methods (riskRFE (L),
L1 WSVM, SCAD/eSCAD, FSV, AROM, L0 WSVM) are used in conjunction with
the linear kernel based weighted SVM, while the nonlinear marker selection methods
(riskRFE (G), KNIFE, L0 KP-WSVM, L1 KP-WSVM) are used in conjunction with
the Gaussian RBF kernel based weighted SVM. For each simulation setting, we restrict
ourselves to when the treatment/disease burden ratio δ1 is equal to 0, but consider
three different values for the marker cost δ2, which is either = 0/0.0001/0.001 units.
The feature selection methods considered here can be broadly categorized into two
groups - (a) Embedded (penalized) methods, which have a separate tuning parameter
for penalizing the L1 or L0 cost, including SCAD, eSCAD, L1 WSVM, L0 WSVM,
FSV, KNIFE and KP-WSVMs. For these methods, δ2, the ratio of the cost of measur-
ing one biomarker to the burden per disease event, is utilized directly for choosing the
optimum value of the respective tuning parameter(s). Although AROM also belongs
to this class, it achieves L0 penalization through an iterative fitting of the L2 norm
SVM. Thus in this case, δ2 is used for choosing the optimum amount of L2 tuning;
and (b) Wrappers that have no separate penalization for the L1 or L0 cost (both
riskRFE(L) and riskRFE(G)); thus are not tuned on the value of δ2. The other global
SVM parameters, such as the width of the Gaussian kernel in nonlinear SVMs, are
tuned based on the prediction performance of the weighted support vector machines
in the full model. In this simulation study, we only consider the double-robustness
weights of Huang and Fong (2014) for obtaining Wi for each individual. As a com-
parative method, we use linear logistic regression model with LASSO and weighted
SVM without feature selection to find the optimal treatment selection rule. In logistic
regression, the P (Y = 1|X, T ) is modeled as a function of the main effects of the treat-
ment and the biomarkers, and the interaction effects between the treatment and the
biomarkers, with the amount of L1 penalization tuned globally through usual cross
validation. This is also the risk model used for constructing the double-robustness
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weights.
In each Monte Carlo simulation, we follow a 5-fold cross-validation procedure to
identify the optimal tuning parameters in the model for a given method. As mentioned
before, we perform this tuning in a two-step procedure - the global SVM parameters
are tuned first using the full model in an weighted SVM analysis. The Hilbert Space
norm of the estimated function (which in linear kernel becomes the L2 norm) is tuned
on a grid of values lying between (0.0001, 100), while the width of the Gaussian kernel,
γ, is tuned over a grid of values lying between (0.001, 10). Then for each of the
embedded methods, we use cross validation to tune for the additional penalization
parameter(s) based on the performance of the method in question, using the selected
global SVM parameters from step one. Each of these parameters was tuned on a grid
of a viable range of values, and the value obtaining the optimal GCV performance
is chosen for that method. This two-step procedure is followed to gain computation
time, and also because the L2 norm allows shrinkage of the estimated effects, rather
than controlling sparsity directly.
The optimal treatment-selection rule Aˆ(Xˆ0), where Xˆ0 ⊆ Xp is the optimal set
of markers chosen by a given method, is then estimated from the training sam-
ple, after retuning the global SVM parameters in the model with the selected mark-
ers. To evaluate the performance of the estimated rule, a test set of n =
5000 is generated in each simulation run, based on which we estimate θ as θˆ =∑n
i=1
{
(1− Ti)× Yi × (1− Aˆ(Xˆ0i))/n0 + Ti × Yi × Aˆ(Xˆ0i)/n1 + δ1Aˆ(Xˆ0i)
}
+ δ2|Xˆ0|. We
evaluate the performance of each method over 100 Monte Carlo runs. In our results, we
present the estimated version of the quantity θ that we evaluate from these Monte Carlo runs.
We compare performance of different methods in the following three settings.
In the first setting, we have in total a list of 27 markers, of which only 2 are sig-
nificant in explaining treatment-marker interactions (|Xp| = 27, |X0| = 2). The sig-
nificant markers, (X1, X2) are generated from the multivariate normal distribution ∼
N
((
0
0
)
,
(
1 0.2
0.2 1
))
. Each of the rest is generated independently from a N(0, 1) dis-
tribution. We consider two subcases under this setting: (i) a ‘linear’ underlying model, given
by logitP (Y = 1|X1, X2, T ) = −1.5− 1.5X1 − 1.25X2 + 2X1T + 1.5X2T , with disease preva-
lence approximately 0.3 and 0.2 among the untreated and treated, respectively; and (ii) a
polynomial ‘nonlinear’ underlying model logitP (Y = 1|X1, X2, T ) = −1.5 + 0.2X1 − 0.2X2 −
3T −X1T −X2T +X21T +X22T , with disease prevalence approximately 0.18 and 0.17 among
the untreated and treated, respectively.
In the second setting, we have in total a list of 53 markers, of which only 3 are sig-
nificant in explaining treatment-marker interactions (|Xp| = 53, |X0| = 3). The sig-
nificant markers, (X1, X2, X3) are generated from the multivariate normal distribution ∼
N
 00
0
 ,
 1 0.2 0.20.2 1 0.2
0.2 0.2 1
. Each of the rest is generated independently from a
N(0, 1)distribution with mean 0 and standard deviation 1. Again we consider two sub-
cases: (i) a ‘linear’ underlying model, given by logitP (Y = 1|X1, X2, X3, T ) = −2 +
X1 + 0.75X2 + X3 − 2X1T − 1.5X2T − 2X3T , with disease prevalence approximately 0.22
among both the untreated and treated groups; and (ii) a ‘nonlinear’ underlying model
logitP (Y = 1|X1, X2, X3, T ) = −0.8−3T −X1T −X2T +X21T +X22T −
√|X3|T , with disease
prevalence approximately 0.30 and 0.18 among the untreated and treated, respectively.
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Table 1. Setting 1(i) (Linear): Setting with disease prevalence approximately 0.30 and
0.20 among the untreated and treated, respectively (Number of markers 27, number of
significant markers 2) - Performance scores: (a) Monte Carlo mean of proportion of correct
markers chosen, (b) Monte Carlo mean of proportion of incorrect markers chosen, (c) Monte
Carlo mean of θ with (i) δ1 = 0 and δ2 = 0, (ii) with δ1 = 0 and δ2 = 0.0001 (iii) with δ1 = 0 and
δ2 = 0.001 for different feature selection methods .
Setting 1 (Underlying model: Linear)
δ1 = 0, δ2 = 0 δ1 = 0, δ2 = 0.0001 δ1 = 0, δ2 = 0.001
Linear Methods E(Prop. E(Prop. E(θ) E(Prop. E(Prop. E(θ) E(Prop. E(Prop. E(θ)
correct)incorrect) correct)incorrect) correct)incorrect)
SCAD 1 0.17 0.1048 1 0.16 0.1069 1 0.01 0.1045
elastic SCAD 1 0.20 0.1076 1 0.18 0.1128 1 0.11 0.1145
L1 WSVM 1 0.31 0.1107 1 0.29 0.1123 1 0.16 0.1109
L0 WSVM 1 0.26 0.1114 1 0.16 0.1105 1 0.08 0.1127
FSV 1 0.32 0.1074 1 0.22 0.1096 1 0.11 0.1075
AROM 0.97 0.10 0.1059 0.97 0.09 0.1079 0.97 0.05 0.1116
riskRFE (L) 1 0.03 0.1016 1 0.03 0.1019 1 0.03 0.1044
LASSO 1 0.29 0.1065 1 0.29 0.1074 1 0.29 0.1158
W-SVM Linear no sel.† 1 1 0.1178 1 1 0.1205 1 1 0.1448
δ1 = 0, δ2 = 0 δ1 = 0, δ2 = 0.0001 δ1 = 0, δ2 = 0.001
Nonlinear Methods E(Prop. E(Prop. E(θ) E(Prop. E(Prop. E(θ) E(Prop. E(Prop. E(θ)
correct)incorrect) correct)incorrect) correct)incorrect)
KNIFE 1 0.27 0.1075 1 0.26 0.1101 1 0.12 0.1120
L1 KP-WSVM 1 0.24 0.1080 1 0.24 0.1094 1 0.09 0.1082
L0 KP-WSVM 1 0.32 0.1113 1 0.27 0.1102 1 0.17 0.1127
riskRFE (G) 1 0.03 0.1021 1 0.03 0.1024 1 0.03 0.1049
W-SVM Gauss no sel.† 1 1 0.1202 1 1 0.1229 1 1 0.1472
† no sel. - no selection
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Table 2. Setting 1(ii) (Nonlinear): Setting with disease prevalence approximately 0.18 and
0.17 among the untreated and treated, respectively (Number of markers 27, number of
significant markers 2) - Performance scores: (a) Monte Carlo mean of proportion of correct
markers chosen, (b) Monte Carlo mean of proportion of incorrect markers chosen, (c) Monte
Carlo mean of θ with (i) δ1 = 0 and δ2 = 0, (ii) with δ1 = 0 and δ2 = 0.0001 (iii) with δ1 = 0 and
δ2 = 0.001 for different feature selection methods.
Setting 1 (Underlying model: Nonlinear)
δ1 = 0, δ2 = 0 δ1 = 0, δ2 = 0.0001 δ1 = 0, δ2 = 0.001
Linear Methods E(Prop. E(Prop. E(θ) E(Prop. E(Prop. E(θ) E(Prop. E(Prop. E(θ)
correct)incorrect) correct)incorrect) correct)incorrect)
SCAD 0.91 0.42 0.1296 0.89 0.32 0.1292 0.85 0.15 0.1322
elastic SCAD 0.96 0.36 0.1289 0.96 0.33 0.1291 0.95 0.23 0.1340
L1 WSVM 0.94 0.43 0.1281 0.94 0.41 0.1296 0.90 0.29 0.1358
L0 WSVM 0.88 0.30 0.1247 0.86 0.29 0.1269 0.82 0.16 0.1314
FSV 0.89 0.32 0.1274 0.90 0.26 0.1266 0.88 0.19 0.1328
AROM 0.91 0.25 0.1269 0.92 0.23 0.1263 0.89 0.16 0.1317
riskRFE (L) 0.85 0.10 0.1223 0.85 0.10 0.1228 0.85 0.10 0.1266
LASSO 0.79 0.19 0.1320 0.79 0.19 0.1326 0.79 0.19 0.1383
W-SVM Linear no sel.† 1 1 0.1349 1 1 0.1376 1 1 0.1619
δ1 = 0, δ2 = 0 δ1 = 0, δ2 = 0.0001 δ1 = 0, δ2 = 0.001
Nonlinear Methods E(Prop. E(Prop. E(θ) E(Prop. E(Prop. E(θ) E(Prop. E(Prop. E(θ)
correct)incorrect) correct)incorrect) correct)incorrect)
KNIFE 0.99 0.35 0.1156 0.97 0.30 0.1147 0.95 0.21 0.1196
L1 KP-WSVM 0.96 0.33 0.1130 0.96 0.31 0.1126 0.93 0.20 0.1183
L0 KP-WSVM 0.97 0.45 0.1191 0.97 0.42 0.1196 0.95 0.35 0.1245
riskRFE (G) 0.88 0.11 0.1178 0.88 0.11 0.1183 0.88 0.11 0.1222
W-SVM Gauss no sel.† 1 1 0.1356 1 1 0.1383 1 1 0.1626
† no sel. - no selection
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Table 3. Setting 2(i) (Linear): Setting with disease prevalence approximately 0.22 among
both the untreated and treated (Number of markers 53, number of significant markers 3) -
Performance scores: (a) Monte Carlo mean of proportion of correct markers chosen, (b) Monte
Carlo mean of proportion of incorrect markers chosen, (c) Monte Carlo mean of θ with (i) δ1 = 0
and δ2 = 0 for different feature selection methods.
Setting 2 (Underlying model: Linear)
δ1 = 0, δ2 = 0 δ1 = 0, δ2 = 0.0001 δ1 = 0, δ2 = 0.001
Linear Methods E(Prop. E(Prop. E(θ) E(Prop. E(Prop. E(θ) E(Prop. E(Prop. E(θ)
correct)incorrect) correct)incorrect) correct)incorrect)
SCAD 0.98 0.31 0.0557 0.97 0.30 0.0582 0.95 0.01 0.0545
elastic SCAD 1 0.30 0.0599 1 0.23 0.0588 1 0.13 0.0642
L1 WSVM 1 0.45 0.0605 1 0.33 0.0574 1 0.14 0.0634
L0 WSVM 0.97 0.23 0.0563 0.96 0.17 0.0565 0.95 0.01 0.0542
FSV 0.95 0.36 0.0594 0.94 0.24 0.0627 0.95 0.12 0.0630
AROM 0.94 0.06 0.0562 0.94 0.04 0.0549 0.94 0.02 0.0598
riskRFE (L) 0.97 0.02 0.0519 0.97 0.02 0.0523 0.97 0.02 0.0558
LASSO 1 0.17 0.0555 1 0.17 0.0567 1 0.17 0.0670
W-SVM Linear no sel. † 1 1 0.0686 1 1 0.0739 1 1 0.1216
δ1 = 0, δ2 = 0 δ1 = 0, δ2 = 0.0001 δ1 = 0, δ2 = 0.001
Nonlinear Methods E(Prop. E(Prop. E(θ) E(Prop. E(Prop. E(θ) E(Prop. E(Prop. E(θ)
correct)incorrect) correct)incorrect) correct)incorrect)
KNIFE 0.98 0.24 0.0557 0.96 0.16 0.0567 0.96 0.03 0.0561
L1 KP-WSVM 0.98 0.19 0.0550 0.98 0.08 0.0539 0.97 0.03 0.0560
L0 KP-WSVM 0.99 0.20 0.0606 0.99 0.17 0.0572 0.99 0.09 0.0630
riskRFE (G) 0.98 0.02 0.0505 0.98 0.02 0.0509 0.98 0.02 0.0545
W-SVM Gauss no sel. † 1 1 0.0681 1 1 0.0734 1 1 0.1211
† no sel. - no selection
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Fig. 2. Simulation setting 3 - Distribution of X1 and X2 marker values for 10000 individuals,
stratified by their membership to the potential harm (red) or the potential benefit (blue) zones.
In the third setting, we consider a complex nonlinear setup, with a total of 27 markers, of
which only 2 are significant in explaining treatment-marker interactions. All of the markers are
generated from the uniform distribution, that is, Xi ∼ U(−2, 2), i = 1, . . . , 27. The model for
treatment marker interaction considers a situation where the treatment has benevolent effect
for an individual only if his/her marker values X1 and X2 lie in a specific region of the covariate
space, without which the treatment might yield a harmful result. This is achieved by dividing
the covariate space spanned by X1 and X2, the square {−2 ≤ X1 ≤ 2,−2 ≤ X2 ≤ 2}, into
two regions: (i) a ‘harmful’ zone given by the smaller square {−1 ≤ X1 ≤ 1,−1 ≤ X2 ≤ 1},
denoted as H; and (ii) a ‘beneficial’ zone given by the region between the two concentric
squares, denoted as B (Figure 2 plots X1 and X2 marker values for 10000 such hypothetical
individuals). Thus, the probability that the treatment is benevolent for the population is 0.75.
The probability of disease for an individual in region B is 0 if the individual receives treatment,
but 0.6 otherwise, and they are reversed for an individual from H. The global probability
for disease in the population is thus fixed at 0.3. The disease prevalences are approximately
around 0.53 and 0.17 among the untreated and treated, respectively.
3.2. Results
The results for the simulation exercise are summarized in Tables 1-5. We give an overview of
these results below, while a more detailed discussion of each of these settings is provided in
the Supplementary Materials (see Web Appendix ??).
(a) While most biomarker-based treatment-selection rules result in reduction of the total cost
compared to the optimal strategy between treating all or treating none, methods that
allow for feature selection lead to substantial improvement compared to the weighted SVM
method without feature selection.
(b) Embedded feature selection methods that involve tuning by marker measure cost δ2 in
general show an decreasing trend in sensitivity and an increasing trend in specificity with
increasing values of δ2, which is not the case for wrapper methods (such as riskRFE) or
LASSO, that do not rely on δ2 for tuning. As a result, for the latter type of methods, the
total cost E(θ) necessarily increases with increasing δ2, the cost of measuring a marker; in
contrast, for methods that involve δ2 in tuning, the total cost E(θ) can often decrease with
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increasing δ2, especially when the improvement in the specificity score for a given method
is more substantial than the decline in its sensitivity score.
(c) In presence of a linear trend, best performing methods are typically among feature selection
methods with linear kernel, yet feature selection methods with nonlinear kernel can have
comparable performance; in presence of nonlinear trends, feature selection methods with
nonlinear kernel can have substantial improvement over linear methods.
(d) Relative performance of various methods vary with settings. In general, riskRFE performs
really well when the cost of marker measurement is low. Apart from it, L1 WSVM, SCAD
and AROM are the best performing linear methods, especially when the cost of marker
measurement is high, while L1 KP-WSVM stands out among the nonlinear feature selection
methods, with robust performance across settings.
We also evaluate these algorithms in a few additional settings. We compare their performance
against that of the Decision List method of Zhang et al. (2015). We also consider a setting
where the true optimal decision rule is not sparse but the effect of some biomarkers on the
optimal treatment decision are so small that given the cost consideration, a sparser decision
rule is more optimal in terms of the criterion θ. For space constraint, these additional settings
are discussed in detail in the Supplementary Materials (Web Appendix ??), and the results
are provided in Supplementary Tables ??, ?? and ??.
4. Real data analysis
We now use an example from the RV144 Thailand HIV vaccine trial to examine the
performance of the methods discussed above for selecting and combining markers.
RV144 is one of the first vaccine trials that showed a significant positive effect of
vaccine in preventing HIV infection. It included 16,402 participants, aged between
18 and 30 years, randomized 1:1 between vaccine and placebo (Rerks-Ngarm et al.,
2009). A followup hostgenetic study was conducted to measure the effect of geno-
types of Fc receptor genes on vaccine efficacy, and to that effect 190 single nucleotide
polymorphisms (SNPs) (including five Fc-γ and one Fc-α receptors) were genotyped
on 125 cases (74 placebo recipients and 51 vaccine recipients), and 225 controls (20
placebo recipients and 205 vaccine recipients), of which 28 SNPs were selected based
on Hardy-Weinberg equilibrium by Li et al. (2014), each categorized into a binary
variable, to study association of each with vaccine efficacy. Here we consider all 28
SNPs as the expensive candidate biomarkers to select from. In addition, age, gender,
and baseline behaviorial risk for vaccine are combined with SNPs for treatment rec-
ommendation as in Huang (2016); no penalty is put on those baseline variables as they
are readily available from the trial. Lifetime HIV treatment cost is estimated to be
around $370K according to CDC (https://www.cdc.gov/hiv/programresources/
guidance/costeffectiveness/index.html). Vaccines typically cost a few hundred
dollars and have minimal side effects, so we set δ1 = 0.001. The average cost of a
SNP evaluation varies between $ 2-4, and hence we consider a range of values for
δ2 ∈ {10−6, 5× 10−6, 10−5} based on the burden of measuring a SNP with respect to
the treatment cost (as 2/370000 ≈ 5 × 10−6). We compare the performance of the
linear and nonlinear feature selection methods to select the optimal subset of markers
for the purposes of vaccine recommendation for an individual. We also use LASSO as
a method of selecting markers and estimating the treatment recommendation rule. A
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Table 4. Setting 2(ii) (Nonlinear): Setting with disease prevalence approximately 0.30 and
0.18 among the untreated and treated, respectively (Number of markers 53, number of
significant markers 3) - Performance scores: (a) Monte Carlo mean of proportion of correct
markers chosen, (b) Monte Carlo mean of proportion of incorrect markers chosen, (c) Monte
Carlo mean of θ with (i) δ1 = 0 and δ2 = 0, (ii) with δ1 = 0 and δ2 = 0.0001 (iii) with δ1 = 0 and
δ2 = 0.001 for different feature selection methods.
Setting 2 (Underlying model: Nonlinear)
δ1 = 0, δ2 = 0 δ1 = 0, δ2 = 0.0001 δ1 = 0, δ2 = 0.001
Linear Methods E(Prop. E(Prop. E(θ) E(Prop. E(Prop. E(θ) E(Prop. E(Prop. E(θ)
correct)incorrect) correct)incorrect) correct)incorrect)
SCAD 0.84 0.65 0.1578 0.74 0.39 0.1588 0.68 0.24 0.1693
elastic SCAD 0.88 0.63 0.1607 0.81 0.47 0.1641 0.77 0.39 0.1821
L1 WSVM 0.76 0.47 0.1597 0.71 0.37 0.1610 0.58 0.18 0.1696
L0 WSVM 0.74 0.33 0.1576 0.69 0.27 0.1621 0.63 0.15 0.1685
FSV 0.83 0.64 0.1597 0.70 0.40 0.1630 0.69 0.33 0.1762
AROM 0.74 0.33 0.1564 0.68 0.24 0.1584 0.65 0.17 0.1653
riskRFE (L) 0.64 0.22 0.1564 0.64 0.22 0.1577 0.64 0.22 0.1693
LASSO 0.59 0.15 0.1636 0.59 0.15 0.1645 0.59 0.15 0.1729
W-SVM Linear no sel.† 1 1 0.1674 1 1 0.1727 1 1 0.2204
δ1 = 0, δ2 = 0 δ1 = 0, δ2 = 0.0001 δ1 = 0, δ2 = 0.001
Nonlinear Methods E(Prop. E(Prop. E(θ) E(Prop. E(Prop. E(θ) E(Prop. E(Prop. E(θ)
correct)incorrect) correct)incorrect) correct)incorrect)
KNIFE 0.79 0.31 0.1435 0.74 0.21 0.1388 0.71 0.07 0.1304
L1 KP-WSVM 0.81 0.53 0.1528 0.62 0.27 0.1513 0.50 0.10 0.1455
L0 KP-WSVM 0.82 0.53 0.1535 0.81 0.47 0.1567 0.77 0.38 0.1642
riskRFE (G) 0.65 0.09 0.1369 0.65 0.09 0.1375 0.65 0.09 0.1432
W-SVM Gauss no sel.† 1 1 0.1645 1 1 0.1698 1 1 0.2175
† no sel. - no selection
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Table 5. Setting 3 (Nonlinear): Setting with disease prevalence approximately 0.53 and
0.17 among the untreated and treated, respectively (Number of markers 27, number of
significant markers 2) - Performance scores: (a) Monte Carlo mean of proportion of correct
markers chosen, (b) Monte Carlo mean of proportion of incorrect markers chosen, (c) Monte
Carlo mean of θ with (i) δ1 = 0 and δ2 = 0 for different feature selection methods.
Setting 3 (Underlying model: Nonlinear)
δ1 = 0, δ2 = 0 δ1 = 0, δ2 = 0.0001 δ1 = 0, δ2 = 0.001
Linear Methods E(Prop. E(Prop. E(θ) E(Prop. E(Prop. E(θ) E(Prop. E(Prop. E(θ)
correct)incorrect) correct)incorrect) correct)incorrect)
SCAD NA NA NA NA NA NA NA NA NA
elastic SCAD NA NA NA NA NA NA NA NA NA
L1 WSVM 0.19 0.18 0.1744 0.17 0.20 0.1749 0.16 0.19 0.1795
L0 WSVM 1 0.99 0.1746 1 1 0.1773 1 1 0.2015
FSV 0.91 0.95 0.1745 0.50 0.52 0.1746 0.50 0.52 0.1873
AROM NA NA NA NA NA NA NA NA NA
riskRFE (L) 0.22 0.29 0.1749 0.22 0.29 0.1757 0.22 0.29 0.1826
LASSO 0.05 0.14 0.1776 0.05 0.14 0.1780 0.05 0.14 0.1812
W-SVM Linear no sel.† 1 1 0.1746 1 1 0.1773 1 1 0.2015
δ1 = 0, δ2 = 0 δ1 = 0, δ2 = 0.0001 δ1 = 0, δ2 = 0.001
Nonlinear Methods E(Prop. E(Prop. E(θ) E(Prop. E(Prop. E(θ) E(Prop. E(Prop. E(θ)
correct)incorrect) correct)incorrect) correct)incorrect)
KNIFE 0.42 0.69 0.1765 0.39 0.68 0.1799 0.40 0.71 0.1958
L1 KP-WSVM 0.88 0.32 0.1100 0.88 0.28 0.1060 0.88 0.26 0.1127
L0 KP-WSVM 1 0.88 0.1621 1 0.89 0.1667 1 0.88 0.1860
riskRFE (G) 0.37 0.08 0.1349 0.37 0.08 0.1352 0.37 0.08 0.1376
W-SVM Gauss no sel.† 1 1 0.1761 1 1 0.1788 1 1 0.2031
† no sel. - no selection
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fivefold CV is performed to select λ, the parameter which controls for overfitting in
the estimated WSVM decision function, and we do the same to select the width of the
Gaussian kernel, whenever it was used. We also employed a fivefold CV to choose the
other tuning parameters, specific to each of the feature selection methods employed.
To compute the expected disease rate for marker selection for each of these methods,
we perform a cross validation procedure by splitting the data into five random folds,
and using four folds for training the WSVM (or LASSO) procedures with the selected
markers, and using the remaining one for testing. The procedure is repeated 100 times
and the average disease rate is computed.
Table 6 shows the estimated performance of different selection strategies along
with the strategy of treating none and treating all. Those two lead to an estimated
HIV infection rate of 8.54 and 6.44 per 1000 persons, respectively, consistent with the
positive vaccine efficacy we observed in the RV144 trial. From Table 6, it is clear that
linear weighted support vector machines (with or without marker selection) does a
better job of treatment recommendation compared to the nonlinear weighted support
vector machines (with or without marker selection) with the Gaussian kernel in this
particular example. It can be seen that both the linear and nonlinear WSVM without
any selection perform at par with the strategy of treating all, even when we consider
a biomarker cost, when it is relatively low, but gets worse with higher values of δ2.
Most of the linear selection methods yield a total cost at least as good as the strategy
of treating all, even when δ2 is high. Among the linear methods, only elastic SCAD
achieves a total cost worse than the strategy of treating all when δ2 is high. On the
other hand, AROM is outperforming every other strategy, followed closely by riskRFE
(L). Overall we can conclude that marker selection is an important formulation for
treatment recommendation using the weighted support vector machines framework.
5. Concluding remarks
In this article, we developed a new framework to incorporate marker measurement
cost into treatment regime identification, with a pre-determined cost for inclusion of
each biomarker in the model. We extended several different marker selection methods
to apply to the weighted support vector machines setting, encompassing both the lin-
ear and the nonlinear space, in order to derive the optimal treatment-selection rules
that minimize the total cost due to disease, treatment, and marker measurements. We
investigated their performance in a number of different setups through a detailed simu-
lation study, and also in a real data scenario, the RV144 HIV vaccine trial. We showed
that in presence of a large number of candidate biomarkers, marker selection is essen-
tial for deriving cost-effective treatment-selection rules that effectively reduces disease
and treatment burdens to the population while avoiding the burdens of collecting in-
formation on irrelevant biomarkers. We showed that marker selection also reduced
the chance of obtaining overfitted treatment recommendation rules, which can result
in lower test disease rate predictions than when we use the full model for treatment
recommendation. It is worthwhile to note here that the indirect approaches can some-
times be inefficient compared with direct approaches, especially when the underlying
disease risk model is correctly specified in the direct approaches. Moreover, inference
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Table 6. Cross-validated treatment-selection performance of var-
ious approaches for making treatment recommendation in the
RV144 trial: Disease cost + vaccine cost + SNP cost - expected dis-
ease rate per 1000 individuals with added cost of vaccine (δ1 = 0.001)
and 3 different costs for marker evaluation (δ2 ∈ {10−6, 5 × 10−6, 10−5}
for each of the 28 SNPs evaluated) for treatment selection with various
methods of marker selection.
Disease cost Disease cost Disease cost
Methods + vaccine cost + vaccine cost + vaccine cost
+SNP cost +SNP cost +SNP cost
δ2 = 10
−6 δ2 = 5× 10−6 δ2 = 10−5
Treat all 7.44 7.44 7.44
Treat none 8.54 8.54 8.54
SCAD 7.21 7.28 7.37
elastic SCAD 7.34 7.44 7.56
L1 WSVM 7.24 7.32 7.42
L0 WSVM 7.31 7.37 7.44
FSV 7.29 7.35 7.43
AROM 6.97 7.03 7.11
riskRFE (L) 7.15 7.17 7.19
LASSO 7.53 7.56 7.60
W-SVM Linear no sel.† 7.42 7.55 7.71
KNIFE 7.33 7.38 7.44
L1 KP-WSVM 7.39 7.46 7.55
L0 KP-WSVM 7.32 7.42 7.55
riskRFE (G) 7.35 7.40 7.46
W-SVM Gauss no sel.† 7.44 7.57 7.73
† no sel. - no selection
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for the estimated optimal regime can become challenging under indirect approaches.
However, these methods are still appealing and provide a complementary alternative
to direct approaches because of their robustness to model misspecifications. In fact,
comparison of our algorithms with logistic regression with LASSO showed that in
some settings, even when the risk model assumptions hold (as was the case in most
of our simulation settings), feature selection using the indirect approaches can lead
to treatment-selection rules with performance comparable to or even better than that
based on direct approaches. Among the various marker selection technique employed
in the simulations, riskRFE stood out as the best performing method when cost of
measuring marker measurement cost was low, while AROM, SCAD and L0 WSVM
were the best performing linear feature selection methods for higher costs of marker
selection, depending on the setting. On the other hand, L1 KP-WSVM was clearly the
best performing nonlinear feature selection method in most of the settings. In general,
we showed that using nonlinear feature selection methods can perform substantially
better than linear feature selection methods in presence of nonlinear patterns, at a
minimal cost of efficiency in presence of linear patterns. One last thing to note here
is that the methodology put forward in this article typically invoke the randomized
setting. However, if the assumptions of (i) SUTVA and (ii) ignorable treatment as-
signment (see Page 5 in Section 2 for more details) hold in an observational setting
too, our proposed methods will continue to be applicable there, although assumption
(ii) is typically not verifiable without randomization.
6. Supplementary Materials
Additional materials referenced in Sections 2 and 3 are available with this paper at
the Journal of Royal Statistical Society Series C web page hosted at the Wiley Online
Library.
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